The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
Clinical trial NCT01777334 · COMPLETED
Trial details
- NCT number
- NCT01777334
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-23
- Primary completion
- 2013-09-24
- Enrollment
- 905
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.